Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 8:10:144.
doi: 10.3389/fphar.2019.00144. eCollection 2019.

Are Regulation and Innovation Priorities Serving Public Health Needs?

Christopher-Paul Milne  1 , Kenneth I Kaitin  1
Affiliations
Review

Are Regulation and Innovation Priorities Serving Public Health Needs?

Christopher-Paul Milne et al. Front Pharmacol. .

Abstract

A host of challenges confront healthcare authorities worldwide. Topping the list is the demand for innovative new medicines to treat a range of both infectious and non-communicable diseases, while containing spiraling healthcare costs. The challenge is particularly great in therapeutic areas where, despite significant medical need and economic impact, the technical challenges and commercial risk of development serve as disincentives to drug sponsors. These areas include cardiovascular diseases as well as diseases and disorders of the central nervous system. Currently, the development and approval of new active substances, with its disproportionate focus on oncology, is not in alignment with healthcare needs in most geographic regions. In this article, we discuss the origins of this misalignment and suggest various approaches to address healthcare needs going forward.

Keywords: drug development; innovation; new active substance (NAS); pharmaceutical R & D; regulatory agency.

PubMed Disclaimer

Figures

Figure 1
Figure 1
2013–2017 NAS approvals by therapeutic area.
Figure 2
Figure 2
2013–2017 NAS, top 4 TAs by top 4 regions.
See this image and copyright information in PMC

References

    1. BCG Henderson Institute (2017). How Asia Can Win in the New Global Era, eds, Bhattacharya A., Rastogi V., Tan M., Burkner H. P. (Boston, MA: Boston Consulting Group; ). Available online at: https://www.bcg.com/en-us/publications/2017/globalization-winning-inemer... (Accessed October 5, 2018).
    1. DiMasi J.A., Faden L. (2009). Factors associated with multiple FDA review cycles and approval phase times. Drug Information J. 43, 201–225. 10.1177/009286150904300212 - DOI
    1. Ferguson C., David S., Divine L., Kahan S., Gallagher C., Gooding M., et al. (2013). Obesity Drug Outcome Measures: A Consensus Report of Considerations on Pharmacologic Interventions, George Washington University School of Public Health and Health Services.
    1. GAO-17-189 (2017). FDA Has Encouraged Development But Needs to Clarify the Role of Draft Guidance and Develop Qualified Infectious Disease Product Guidance. Available online at: https://www.gao.gov/assets/690/682702.pdf (Accessed December 4, 2018).
    1. Haley S. (2013). ALS patients ask FDA to see risk their way. Pink Sheet 75, 30–32.

LinkOut - more resources